Anti-MUC1 Antibody in Nipple Aspirate Fluids Correlates with Tumor Aggressiveness in Breast Cancer: A Feasibility Study
Table 2
Anti-MUC1 antibody levels of breast cancer patients in NAF and serum samples.
Anti-MUC1 levels (mean ± SD) (OD 405 nm)
Tumor characteristic
IgG
IgM
IgA
NAF ()
Triple negative
0.02
0.12
0.90
Absent ()
0.10 ± 0.07
0.17 ± 0.16
0.23 ± 0.16
Present ()
0.20 ± 0.20
0.29 ± 0.23
0.24 ± 0.09
Her2-neu
0.42
0.35
0.02
(−) ()
0.11 ± 0.11
0.17 ± 0.16
0.21 ± 0.12
(+) ()
0.14 ± 0.08
0.25 ± 0.25
0.36 ± 0.25
LVI
0.85
0.75
0.005
(−) ()
0.11 ± 0.11
0.19 ± 0.19
0.21 ± 0.12
(+) ()
0.10 ± 0.27
0.16 ± 0.10
0.40 ± 0.25
Serum ()
Estrogen receptor
0.01
0.93
0.70
(−) ()
0.53 ± 0.83
0.99 ± 0.48
0.26 ± 0.09
(+) ()
0.16 ± 0.19
0.97 ± 0.60
0.29 ± 0.19
Tumor size (T)
0.03
cm ()
0.26 ± 0.46
1.08 ± 0.63
0.27 ± 0.15
cm ()
0.12 ± 0.08
0.68 ± 0.28
0.32 ± 0.25
Recurrence
0.01
0.86
0.24
Absent ()
0.18 ± 0.21
0.98 ± 0.59
0.29 ± 0.18
Present ()
0.70 ± 1.30
0.93 ± 0.59
0.18 ± 0.10
One missing data in NAF sample for triple negativity and Her2-neu status and two missing data in NAF samples for LVI status from 44 malignant breast lesions. One missing data for serum samples from 52 patients with malignant. LVI: lymphovascular invasion and NAF: nipple aspirate fluid.
